The researchers running these trials say the case is not made
A review by the principal investigators accepts that NAD falls with age and that precursors raise it safely, then asks for powered trials before any therapeutic claim.
What the study found
Even the field's own investigators call the mechanism unsettled
A review by the investigators running trials of nicotinamide adenine dinucleotide (NAD) precursors accepts that NAD falls with age and that oral precursors raise it safely in blood and some tissues. On what follows, it asks for adequately powered trials before any therapeutic claim.
The caveat · The field appraising itself
A narrative appraisal rather than a systematic review, so its selection of evidence cannot be reproduced by anyone else. Its authors include the group running the pharmaceutical NMN trials, which makes this the field appraising itself. Its phrase about raising NAD in blood and some tissues is deliberately narrower than the marketing and should not be read as delivery throughout the body.